Trademark: 79295861
Word
ONE-SITE-STOP
Status
Registered
Status Code
700
Status Date
Tuesday, March 1, 2022
Serial Number
79295861
Registration Number
6655646
Registration Date
Tuesday, March 1, 2022
Mark Type
4000
Filing Date
Tuesday, June 2, 2020
Published for Opposition
Tuesday, December 14, 2021

Trademark Owner History
Hovione Scientia Limited - Original Registrant

Classifications
5 Compositions for medical and veterinarian use, namely, chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; diagnostic preparations for medical purposes; chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals
1 Active chemical ingredients for use in the manufacture of pharmaceuticals for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals
42 Development of pharmaceutical products and drug products; research on pharmaceutical products and drug products; research and development of new products in the pharmaceutical industry; consulting services in the field of design and development of engineering processes for the pharmaceutical industry; research and development services in the pharmaceutical field; research and development services in the field of pharmaceuticals, chemical preparations, vaccines, medicines, antibodies, new products in the medical field

Trademark Events
Sep 18, 2022
New Representative At Ib Received
Aug 22, 2022
Final Decision Transaction Processed By Ib
Aug 3, 2022
Final Disposition Notice Sent To Ib
Aug 3, 2022
Final Disposition Processed
Jun 1, 2022
Final Disposition Notice Created, To Be Sent To Ib
Mar 1, 2022
Registered-Principal Register
Dec 19, 2021
Notification Processed By Ib
Dec 14, 2021
Official Gazette Publication Confirmation E-Mailed
Dec 14, 2021
Published For Opposition
Nov 24, 2021
Notification Of Possible Opposition Sent To Ib
Nov 24, 2021
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Nov 24, 2021
Notification Of Notice Of Publication E-Mailed
Nov 9, 2021
Approved For Pub - Principal Register
Nov 9, 2021
Teas/Email Correspondence Entered
Nov 9, 2021
Correspondence Received In Law Office
Nov 9, 2021
Assigned To Lie
Nov 4, 2021
Teas Request For Reconsideration Received
Nov 4, 2021
Examiner's Amendment Entered
Nov 4, 2021
Notification Of Examiners Amendment E-Mailed
Nov 4, 2021
Examiners Amendment E-Mailed
Nov 4, 2021
Examiners Amendment -Written
May 14, 2021
New Representative At Ib Received
May 13, 2021
Notification Of Final Refusal Emailed
May 13, 2021
Final Refusal E-Mailed
May 13, 2021
Final Refusal Written
May 5, 2021
Teas/Email Correspondence Entered
May 4, 2021
Correspondence Received In Law Office
May 4, 2021
Teas Response To Office Action Received
Nov 29, 2020
Refusal Processed By Ib
Nov 10, 2020
Non-Final Action Mailed - Refusal Sent To Ib
Nov 10, 2020
Refusal Processed By Mpu
Oct 23, 2020
Application Filing Receipt Mailed
Oct 21, 2020
Non-Final Action (Ib Refusal) Prepared For Review
Oct 20, 2020
Non-Final Action Written
Oct 19, 2020
Assigned To Examiner
Oct 19, 2020
New Application Office Supplied Data Entered In Tram
Oct 15, 2020
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24